Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2026-03-20 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding a 'Capital Reduction' (감자 결정). This involves a corporate action affecting the company's capital structure (share consolidation). Since it is a specific regulatory announcement regarding a capital change/restructuring, it falls under the 'Share Issue/Capital Change' category, which covers capital structure modifications including share consolidation/reduction.
2026-03-20 Korean
불성실공시법인지정예고
Regulatory Filings Classification · 95% confidence The document is a formal notice from the Korea Exchange (KRX) regarding a 'Notice of Designation as an Unfaithful Disclosure Corporation' (불성실공시법인지정예고). This is a regulatory notification concerning a company's failure to comply with disclosure requirements (delayed disclosure of a change in major shareholder). Since this is a specific regulatory announcement regarding compliance and potential penalties, it falls under the 'Regulatory Filings' category as it does not fit into the specific financial reporting or corporate action categories provided.
2026-03-19 Korean
최대주주변경
Major Shareholding Notification Classification · 97% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a change in the company's largest shareholder (최대주주변경). It details the before-and-after shareholding status, the reason for the change (market sale by the previous largest shareholder), and lists the specific entities involved. This type of disclosure is a standard regulatory requirement for public companies to notify the market of significant changes in control or major shareholding structures. It does not fit into specific categories like M&A or Director's Dealing, but rather falls under general regulatory disclosure requirements for shareholding changes.
2026-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Jinon Life Sciences. It contains the meeting agenda, date, location, and details regarding electronic voting, as well as management information such as board activities and remuneration. This type of document is standard for proxy solicitation and providing shareholders with the necessary information to vote at an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM), including the date, purpose, and instructions for shareholders to exercise their voting rights via proxy, electronic voting, or in person. It also includes financial statements as part of the meeting agenda materials. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-16 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by GeneOne Life Science. It outlines the date, location, and agenda items for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.